{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:15:24Z","timestamp":1765808124012,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T00:00:00Z","timestamp":1670716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T00:00:00Z","timestamp":1670716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Multiple myeloma remains incurable despite treatment advancements over the last 20\u00a0years. LCAR-B38M Cells in Treating Relapsed\/Refractory Multiple Myeloma was a phase 1, first-in-human, investigator-initiated study in relapsed\/refractory multiple myeloma conducted at four sites in China. The study used LCAR-B38M chimeric antigen receptor-T cells expressing two B-cell maturation antigen-targeting single-domain antibodies designed to confer avidity, and a CD3\u03b6 signaling domain with a 4-1BB costimulatory domain to optimize T-cell activation and proliferation. This chimeric antigen receptor construct is identical to ciltacabtagene autoleucel. In the LEGEND-2 study (<jats:italic>n<\/jats:italic>\u2009=\u200957, Xi\u2019an site), overall response rate was 88%; median (95% CI) progression-free survival and overall survival were 19.9 (9.6\u201331.0) and 36.1 (26.4\u2013not evaluable) months, respectively; and median follow-up was 25\u00a0months. This case study reports on a patient with relapsed\/refractory multiple myeloma (\u03bb light chain type) who was treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study (Xi\u2019an site); he had received five prior lines of treatment and had extensive extramedullary lesions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>The patient, a 56-year-old Asian male, received cyclophosphamide (500\u00a0mg daily\u2009\u00d7\u20093\u00a0days) as lymphodepletion therapy and a total dose of 0.5\u2009\u00d7\u200910<jats:sup>6<\/jats:sup> chimeric antigen receptor\u2009+\u2009T cells\/kg split into three infusions (days 1, 24, and 84 from June to August 2016). He experienced grade 2 cytokine release syndrome after the first infusion; all symptoms resolved with treatment. No cytokine release syndrome occurred following the second and third infusions. His \u03bb light chain levels decreased and normalized 20\u00a0days after the first infusion, and extramedullary lesions were healed as of January 2018. He has sustained remission for 5\u00a0years and received no other multiple myeloma treatments after LCAR-B38M chimeric antigen receptor T cell infusion. As of 30 October 2020, the patient is still progression-free and has maintained minimal residual disease-negative (10<jats:sup>\u20134<\/jats:sup>) complete response status for 52\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This case provides support that treatment with LCAR-B38M chimeric antigen receptor T cells can result in long-term disease remission of 5 or more years without disease progression in a heavily pretreated patient with extensive extramedullary disease and no other treatment options.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-022-03636-9","type":"journal-article","created":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T01:02:37Z","timestamp":1670720557000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Five-year remission without disease progression in a patient with relapsed\/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2  study: a\u00a0case report"],"prefix":"10.1186","volume":"16","author":[{"given":"Bai-Yan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Hong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin-Xia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing-Mei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang-Xia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng-Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu-Fang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu-Geng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Li","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu-Chuan","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang-Gang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-Li","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0777-4338","authenticated-orcid":false,"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,11]]},"reference":[{"issue":"11","key":"3636_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046\u201360.","journal-title":"N Engl J Med"},{"key":"3636_CR2","doi-asserted-by":"crossref","first-page":"232546","DOI":"10.1155\/2014\/232546","volume":"2014","author":"S de Mel","year":"2014","unstructured":"de Mel S, Lim SH, Tung ML, Chng WJ. Implications of heterogeneity in multiple myeloma. BioMed Res Int. 2014;2014:232546.","journal-title":"BioMed Res Int"},{"issue":"3","key":"3636_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3324\/haematol.2016.152504","volume":"102","author":"P Rodr\u00edguez-Otero","year":"2017","unstructured":"Rodr\u00edguez-Otero P, Paiva B, Engelhardt M, Pr\u00f3sper F, San Miguel JF. Is immunotherapy here to stay in multiple myeloma? Haematologica. 2017;102(3):423\u201332.","journal-title":"Haematologica"},{"issue":"9","key":"3636_CR4","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, et\u00a0al. Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018;4(9):1221\u20137.","journal-title":"JAMA Oncol"},{"key":"3636_CR5","unstructured":"Cancer stat facts: myeloma. 2020. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed 9 Oct 2020."},{"issue":"2","key":"3636_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.14213","volume":"175","author":"K Yong","year":"2016","unstructured":"Yong K, Delforge M, Driessen C, et\u00a0al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175(2):252\u201364.","journal-title":"Br J Haematol"},{"key":"3636_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.leukres.2017.05.019","volume":"59","author":"C Hulin","year":"2017","unstructured":"Hulin C, Hansen T, Heron L, et\u00a0al. Living with the burden of relapse in multiple myeloma from the patient and physician perspective. Leuk Res. 2017;59:75\u201384.","journal-title":"Leuk Res"},{"issue":"9","key":"3636_CR8","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, et\u00a0al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266\u201375.","journal-title":"Leukemia"},{"issue":"1","key":"3636_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","volume":"34","author":"M Bhutani","year":"2020","unstructured":"Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ. Extramedullary multiple myeloma. Leukemia. 2020;34(1):1\u201320.","journal-title":"Leukemia"},{"key":"3636_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.blre.2019.04.002","volume":"36","author":"S Sevcikova","year":"2019","unstructured":"Sevcikova S, Minarik J, Stork M, Jelinek T, Pour L, Hajek R. Extramedullary disease in multiple myeloma\u2014controversies and future directions. Blood Rev. 2019;36:32\u20139.","journal-title":"Blood Rev"},{"issue":"2","key":"3636_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdp329","volume":"21","author":"M Varettoni","year":"2010","unstructured":"Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21(2):325\u201330.","journal-title":"Ann Oncol"},{"issue":"11","key":"3636_CR12","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","volume":"97","author":"SZ Usmani","year":"2012","unstructured":"Usmani SZ, Heuck C, Mitchell A, et\u00a0al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97(11):1761\u20137.","journal-title":"Haematologica"},{"issue":"6","key":"3636_CR13","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/leu.2011.29","volume":"25","author":"KD Short","year":"2011","unstructured":"Short KD, Rajkumar SV, Larson D, et\u00a0al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia. 2011;25(6):906\u20138.","journal-title":"Leukemia"},{"issue":"11","key":"3636_CR14","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2217\/imt.15.77","volume":"7","author":"Y Tai","year":"2015","unstructured":"Tai Y, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7(11):1187\u201399.","journal-title":"Immunotherapy"},{"issue":"22","key":"3636_CR15","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Maric I, Hartman SD, et\u00a0al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36(22):2267\u201380.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3636_CR16","doi-asserted-by":"publisher","first-page":"e346","DOI":"10.1002\/ctm2.346","volume":"11","author":"C Li","year":"2021","unstructured":"Li C, Cao W, Que Y, et\u00a0al. A phase I study of anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia. Clin Transl Med. 2021;11(3):e346.","journal-title":"Clin Transl Med"},{"issue":"8","key":"3636_CR17","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, et\u00a0al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"key":"3636_CR18","doi-asserted-by":"publisher","first-page":"755866","DOI":"10.3389\/fimmu.2021.755866","volume":"12","author":"Y Que","year":"2021","unstructured":"Que Y, Xu M, Xu Y, et\u00a0al. Anti-BCMA CAR-T cell therapy in relapsed\/refractory multiple myeloma patients with extramedullary disease: a single center analysis of two clinical trials. Front Immunol. 2021;12:755866.","journal-title":"Front Immunol"},{"key":"3636_CR19","unstructured":"Madduri D, Berdeja JG, Usmani SZ, et al. CARTITUDE-1: phase 1b\/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen\u2013directed chimeric antigen receptor T cell therapy, in relapsed\/refractory multiple myeloma [abstract 177]. Presented at: Annual meeting and exposition of the American Society of Hematology; December 5\u20138, 2020; Virtual."},{"issue":"1","key":"3636_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"WH Zhao","year":"2018","unstructured":"Zhao WH, Liu J, Wang BY, et\u00a0al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11(1):141.\u00a0","journal-title":"J Hematol Oncol"},{"issue":"18 suppl","key":"3636_CR21","doi-asserted-by":"publisher","first-page":"LBA3001","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA3001","volume":"35","author":"F Fan","year":"2017","unstructured":"Fan F, Zhao W, Liu J, et\u00a0al. Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory\/relapsed multiple myeloma [abstract]. J Clin Oncol. 2017;35(18 suppl):LBA3001.","journal-title":"J Clin Oncol"},{"key":"3636_CR22","doi-asserted-by":"crossref","unstructured":"Fan X, Zhuang Q, Yang L, et\u00a0al. Preclinical assessment of LCAR-B38M, a novel BCMA-targeting chimeric antigen receptor (CAR)-T cell therapy in relapsed\/refractory multiple myeloma [abstract]. Presented at: Biennial International Myeloma Workshop; September 12\u201315, 2019; Boston, MA.","DOI":"10.1016\/j.clml.2019.09.267"},{"issue":"3","key":"3636_CR23","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842\u201354.","journal-title":"Cancer"},{"issue":"15","key":"3636_CR24","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, et\u00a0al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412\u201320.","journal-title":"J Clin Oncol"},{"issue":"19","key":"3636_CR25","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","volume":"116","author":"J Xu","year":"2019","unstructured":"Xu J, Chen LJ, Yang SS, et\u00a0al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma. Proc Natl Acad Sci USA. 2019;116(19):9543\u201351.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 1","key":"3636_CR26","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood-2019-124953","volume":"134","author":"B Wang","year":"2019","unstructured":"Wang B, Zhao W, Liu J, et\u00a0al. Long-term follow-up of a phase 1, first-in-human open-label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell maturation antigen (BCMA), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) [abstract]. Blood. 2019;134(Suppl 1):579.","journal-title":"Blood"},{"issue":"suppl 1","key":"3636_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2020-136307","volume":"136","author":"D Madduri","year":"2020","unstructured":"Madduri D, Berdeja JG, Usmani SZ, et\u00a0al. CARTITUDE-1: phase 1b\/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed\/refractory multiple myeloma [abstract]. Blood. 2020;136(suppl 1):22\u20135.","journal-title":"Blood"},{"issue":"suppl 1","key":"3636_CR28","first-page":"26","volume":"136","author":"Y Lin","year":"2020","unstructured":"Lin Y, Raje NS, Berdeja JG, et\u00a0al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: updated results from phase 1 CRB-401 study [abstract]. Blood. 2020;136(suppl 1):26\u20137.","journal-title":"Blood"},{"issue":"10297","key":"3636_CR29","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, et\u00a0al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324.","journal-title":"Lancet"},{"key":"3636_CR30","doi-asserted-by":"crossref","unstructured":"Zudaire E, Madduri D, Usmani SZ, et\u00a0al. Translational analysis from CARTITUDE-1, an ongoing phase 1b\/2 study of JNJ-4528 BCMA-targeted CAR-T cell therapy in relapsed and\/or refractory multiple myeloma (R\/R MM), indicates preferential expansion of CD8+ T cell central memory cell subset [abstract]. Blood. 2019;134(suppl 1):928. Presented at: 63rd American Society of Hematology annual meeting & exposition; December 7\u201310, 2019; Orlando, FL.","DOI":"10.1182\/blood-2019-127309"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03636-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-022-03636-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03636-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T01:02:45Z","timestamp":1670720565000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-022-03636-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,11]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3636"],"URL":"https:\/\/doi.org\/10.1186\/s13256-022-03636-9","relation":{},"ISSN":["1752-1947"],"issn-type":[{"type":"electronic","value":"1752-1947"}],"subject":[],"published":{"date-parts":[[2022,12,11]]},"assertion":[{"value":"13 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The LEGEND-2 study was performed in accordance with the Declaration of Helsinki and was approved by the institutional independent ethics committee (Reference number: 2016002) of The Second Affiliated Hospital of Xi\u2019an Jiaotong University. The patient has consented and agreed to publication and images included within the case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Q-CZ and FF are employees of Nanjing Legend Biotech Co. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"459"}}